TransMedics Appoints Gerardo Hernandez As CFO And Provides Updated 2024 Financial Outlook; Now Expects Revenue For FY24 To Be In The Range Of $428M-$432M Vs $432.37M Est.
TransMedics Appoints Gerardo Hernandez As CFO And Provides Updated 2024 Financial Outlook; Now Expects Revenue For FY24 To Be In The Range Of $428M-$432M Vs $432.37M Est.
TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025, before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagement until March 31, 2026. TransMedics also updated its 2024 financial outlook.
Transmedics集團（"Transmedics"）（納斯達克股票代碼：TMDX）是一家醫療科技公司，致力於改變終末期肺部、心臟和肝臟衰竭患者的器官移植治療，今日宣佈任命Gerardo Hernandez先生爲公司首席財務官，任命自2024年12月2日起生效。在這一職務上，Hernandez先生加入Transmedics的執行領導團隊，接替Stephen Gordon先生。爲實現平穩過渡，Gordon先生將繼續擔任公司的非執行員工，直至2025年3月31日，然後將擔任公司的非僱員高級顧問，重點關注國家移植利益相關者的參與，直至2026年3月31日。TransMedics還更新了其2024年財務展望。
2024 Financial Outlook
TransMedics now expects revenue for the full year 2024 to be in the range of $428 million to $432 million, which represents 77% to 79% growth compared to the Company's prior year revenue.
2024年財務展望。
TransMedics現預計2024年全年營收爲42800萬至43200萬美元，相較公司前一年的營收增長77%至79%。
譯文內容由第三人軟體翻譯。
